Compare AU
Compare CURE vs. ESGI
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the VanEck MSCI International Sustainable Equity ETF (ESGI). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | ESGI | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 76 | 1,257 |
Median incremental investment | $651.42 | $750.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,269.60 | $2,024.46 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | ESGI | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | The fund exists to track the performance of the MSCI World ex-Australia ex-Fossil Fuel Select SRI and Low Carbon Capped Index before considering any fees, expenses, and taxes. |
Top 3 holdings | Exact Sciences Corp (3.25 %) Alnylam Pharmaceuticals Inc (3.03 %) Neurocrine Biosciences Inc (2.99 %) | ASML Holding NV (5.40 %) Intuit Inc (3.99 %) Adobe Inc (3.73 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Information Technology (45.66 %) Industrials (23.21 %) Other (15.14 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (45.82 %) Japan (9.48 %) Netherlands (6.76 %) |
Management fee | 0.45 % | 0.55 % |
Key Summary
CURE | ESGI | |
|---|---|---|
Issuer | Global X | VanEck |
Tracking index | S&P Biotechnology Select Industry | MSCI World ex Australia ex Fossil Fuel Select SRI and Low Carbon Capped Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.55 % |
Price | $42.32 | $37.62 |
Size | $28.877 million | $209.896 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 3.26 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 08/03/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | ESGI | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 76 | 1,257 |
Median incremental investment | $651.42 | $750.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,269.60 | $2,024.46 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | ESGI | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | ESGI |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |